PhoenixBio Co., Ltd. (6190.T)
JPY 335.0
(-1.76%)
JPY 335.0
(-1.76%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 917.71 Million JPY | -38.99% |
| 2022 | 1.5 Billion JPY | 3.57% |
| 2021 | 1.45 Billion JPY | 2.11% |
| 2020 | 1.42 Billion JPY | -12.34% |
| 2019 | 1.62 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 916 Million JPY | -0.19% |
| 2023 Q4 | 917.71 Million JPY | -0.66% |
| 2023 Q3 | 923.77 Million JPY | -39.5% |
| 2023 Q1 | 1.46 Billion JPY | -2.43% |
| 2023 Q2 | 1.52 Billion JPY | 4.03% |
| 2023 FY | 917.71 Million JPY | -38.99% |
| 2022 Q3 | 1.26 Billion JPY | -12.11% |
| 2022 Q2 | 1.44 Billion JPY | 0.0% |
| 2022 Q4 | 1.5 Billion JPY | 18.53% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 71.736% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -1347.246% |
| GNI Group Ltd. | 26.34 Billion JPY | 96.516% |
| Linical Co., Ltd. | 10.3 Billion JPY | 91.094% |
| Trans Genic Inc. | 3.81 Billion JPY | 75.929% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -55.491% |
| Soiken Holdings Inc. | 697.02 Million JPY | -31.662% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 69.62% |
| AnGes, Inc. | 2.78 Billion JPY | 67.1% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -78.68% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 98.985% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -159.776% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 44.377% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -94.285% |
| CanBas Co., Ltd. | 91.98 Million JPY | -897.644% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 16.084% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -13.322% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -54.567% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 78.427% |
| PeptiDream Inc. | 29.11 Billion JPY | 96.848% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -61.997% |
| Ribomic Inc. | 155.8 Million JPY | -488.999% |
| SanBio Company Limited | 2.25 Billion JPY | 59.301% |
| Healios K.K. | 11.28 Billion JPY | 91.869% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -265.231% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -148.703% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -280.01% |
| StemRIM | 187 Million JPY | -390.756% |
| CellSource Co., Ltd. | 677.73 Million JPY | -35.408% |
| FunPep Company Limited | 189.32 Million JPY | -384.731% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -53.732% |
| Stella Pharma Corporation | 1.44 Billion JPY | 36.429% |
| TMS Co., Ltd. | 97.68 Million JPY | -839.423% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -903.031% |
| Cuorips Inc. | 200.96 Million JPY | -356.662% |
| K Pharma,Inc. | 209.13 Million JPY | -338.816% |
| Takara Bio Inc. | 11.42 Billion JPY | 91.964% |
| ReproCELL Incorporated | 741.03 Million JPY | -23.843% |
| StemCell Institute Inc. | 3.85 Billion JPY | 76.166% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -1.022% |
| CellSeed Inc. | 301.04 Million JPY | -204.84% |